Atossa Therapeutics (MEX:ATOS) Other Financing: MXN0.00 Mil (TTM As of Mar. 2026)


MEX:ATOS Atossa Therapeutics Inc MEX:ATOS
28 GF Score
Price MXN32.50
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Other Financing?

Atossa Therapeutics MEX:ATOS +4.84% 28 Other Financing is MXN0.00 Mil as of Mar. 2026. GuruFocus rates MEX:ATOS with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Atossa Therapeutics's Other Financing for the three months ended in Mar. 2026 was MXN0.00 Mil.

Atossa Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0.00 Mil.

Atossa Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Atossa Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics Other Financing Chart

Atossa Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 895.15 0.00 0.00 0.00 0.00

Atossa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:ATOS
28GF Score
Atossa Therapeutics Inc MEX:ATOS
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of MXN0.00 Mil mean?
Atossa Therapeutics (MEX:ATOS) has a Other Financing of MXN0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Atossa Therapeutics and its competitors.
Is Atossa Therapeutics' Other Financing too high?
Atossa Therapeutics' current Other Financing is MXN0.00 Mil. Overall, Atossa Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' Other Financing compare to LTRN and ESLA?
Atossa Therapeutics' Other Financing of MXN0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Atossa Therapeutics and its competitors. Atossa Therapeutics's current Other Financing is MXN0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (MEX:ATOS) has a current Other Financing of MXN0.00 Mil. The current Other Financing is MXN0.00 Mil. Atossa Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Atossa Therapeutics (MEX:ATOS), the current Other Financing is MXN0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atossa Therapeutics Business Description

Other Exchanges ATOS:USAYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
28GF Score

Get the complete analysis for MEX:ATOS

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN32.50
Price